drugset / Trial / NCT01782937
An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis
NaSingle-groupOpen-labelTreatment
Summary
This study is an open-label, non-controlled study to evaluate the efficacy and safety of KHK4827 in subjects with pustular psoriasis (generalized) and psoriatic erythroderma. Pharmacokinetics of KHK4827 will also be assessed.
Timeline
- Start
- 2013-02
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brodalumab | Monoclonal antibody | 140 mg | — |
| Subject | Brodalumab | Monoclonal antibody | 210 mg | — |